Brophy Wealth Management LLC Invests $809,000 in United Therapeutics Co. (NASDAQ:UTHR)

Brophy Wealth Management LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,258 shares of the biotechnology company's stock, valued at approximately $809,000.

Several other institutional investors also recently bought and sold shares of UTHR. Cetera Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter valued at about $475,000. CWM LLC increased its holdings in United Therapeutics by 11.0% during the 2nd quarter. CWM LLC now owns 1,923 shares of the biotechnology company's stock worth $613,000 after purchasing an additional 191 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $205,000. Wealth Enhancement Advisory Services LLC grew its holdings in United Therapeutics by 3.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company's stock worth $849,000 after acquiring an additional 81 shares in the last quarter. Finally, V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth about $30,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $3.19 on Tuesday, hitting $363.81. The company's stock had a trading volume of 74,952 shares, compared to its average volume of 449,421. The company has a market capitalization of $16.24 billion, a price-to-earnings ratio of 16.12, a price-to-earnings-growth ratio of 1.07 and a beta of 0.55. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock's 50-day moving average is $369.31 and its two-hundred day moving average is $340.14.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the firm posted $5.38 EPS. United Therapeutics's revenue was up 22.9% compared to the same quarter last year. Equities analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 119,340 shares of company stock worth $44,765,530 over the last quarter. 11.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on UTHR shares. Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Jefferies Financial Group raised their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research note on Tuesday, August 20th. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, TD Cowen raised their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.